Cellular Immunotherapies

• Cellular immunotherapy has developed by leaps and bounds in recent years, providing a cure for many difficult-to-treat cancers.  
  Medicilon has built a one-stop platform for preclinical R&D of cellular immunotherapies, covering a variety of methods including CAR-T, TCR-T and CAR-NK.  Using a wealth of animal models and a variety of advanced analysis techniques, Medicilon has completed numerous pre-clinical projects for clients worldwide.

Introduction to the Test Product

• Category：
  CAR-T CellTCR-T CellCAR-NK CellDNT CellTIL Cell
• The complexity of Immune Cells:
  Proliferation in vivoIndividualization and heterogeneityLimited batches and productionComplicated preparation processRaw materials with huge variationsComplex biological efficacy and safety evaluation

Pharmacology and Pharmacodynamics of Cell & Gene Therapy Drugs

• Safety Pharmacology
  Potential undesired effects of the study drug on physiological function at doses within or above the therapeutic rangeGenerally include effects on the central nervous system, cardiovascular system, and respiratory systemEffects on other organ systems may need to be assessed depending on product characteristics
• In vitro Pharmacodynamic Studies
  Efficacy testing of cell therapy (such as CAR-T):Tumor killing rate or proliferation inhibition rateIFN-γ expression levelPhenotype changes of CAR-T cells
  Preparation and Evaluation of CAR-T
  
  Plasmid Vector Construction
  The PD-1 shRNA was integrated into the CAR plasmid, and then transduced into T cells by a lentiviral vector to obtain CAR-T cells with PD-1 silencing function.  The results showed that effective silencing of PD-1 significantly suppressed the immunosuppressive effect of the tumor microenvironment and prolonged the activation time of CAR-T cells, resulting in a longer tumor killing effect.  PD-1-silenced CAR-T cells significantly prolong the survival of mice with subcutaneous prostate and leukemia xenografts.  This demonstrated that PD-1 silencing technology is a suitable solution to promote the therapeutic effect of CAR-T cells on subcutaneous prostate and leukemia xenografts[1].  The plasmid sequencing work in this experiment was completed by Medicilon.
  
  CAR-T Cell Killing Assay
  
  Experiments assessing CAR-T cell-mediated killing, show that CAR-T-dependent killing is increased significantly compared with Mock-T cells
• In vivo Pharmacodynamic Studies
  Cell Therapy Test Substances
  Can be prepared from blood donated by healthy volunteers Some proof-of-concept studies could be done with alternative products of animal origin The similarities and differences between non-clinical test substances and clinical samples should be detailed in new drug applications
  Gene Therapy Test Substance
  Consider factors such as production process, key quality characteristics (such as titer), preparations for clinical use The activity of the test substance in non-clinical research should be evaluated to investigate If there is species specificity, If the vector uses an expression tag, the impact of the tag on the supportability of non-clinical trials should be analyzed
  Detection Methods and Evaluation Indicators
  Bioluminescent Imaging (BLI) Flow Cytometry: Detecting the number of tumor cells in animals Flow Cytometry, ELISA, MSD: Changes in tumor-related cytokinesRelated Parameters: Tumor volume, tumor weight, tumor cell colonization site in animals and median survival period of animals
  Model Resources：
  Homologous Mouse ModelTransgenic Mouse ModelTransplanted Tumor Mouse Model

                 

  

  The picture shows the pharmacodynamic study of dual-target CAR-T cells in K 562 subcutaneously transplanted tumor mouse model
  Humanized Mouse Model of Immune System Reconstruction
  
  
  △The figure shows the pharmacodynamic study of the mouse pharmacodynamic model of hPBMC immune system reconstruction induced by Raji-luc fluorescein-labeled lymphoma cells
  Bispecific CAR-T Efficacy Research: CD19/BCMA
  
  CAR-T cell killing experiments show that CAR-T cell-dependent killing is increased compared with Mock-T cells

Pharmacokinetic Study of Cell & Gene Therapy Drugs

• Points to Consider for Pharmacokinetic Studies:
  The pharmacokinetc research studies sample in vivo behaviors, such as distribution, proliferation and survival time. We also track transgenic product expressed and secreted outside of the immune cells to assess its local and/or systemic exposure characteristics.
  Exposure: Gene therapy products should be analyzed and evaluated according to the specific characteristics of the product considering the actual exposure in non-clinical researchBiodistribution: Biodistribution of gene therapy products refers to the distribution, persistence and clearance of gene therapy products in target and non-target tissues in vivoShedding: Shedding assays should include testing for infectivity of excreted components
• Pharmacokinetic (Biodistribution) Detection Technology：
  Imaging TechnologyFlow CytometryImmunohistochemical TechniqueQuantitative PCR TechnologyddPCRELISPot
  Distribution of Lung Cell Therapy
  
  The data obtained by qPCR and flow cytometry are consistent
  

Nonclinical Safety Evaluation of Cell & Gene Therapy Drugs

• In toxicology research, a comprehensive safety analysis and evaluation of gene therapy products should be conducted, and the safety of the expression products of introduced genes should also be evaluated if necessary.  Gene therapy products should be effectively introduced/exposed in relevant animal species.
  The non-clinical safety risks of cell therapy (such as CAR-T cells) mainly include:
  Cytokine release syndrome (CRS)Graft-versus-host disease (GVHD)Reversible neurotoxicityReduction of B cellsOn-target/off-tumorTumorigenicity/tumorigenicity
  Model Resources:
  Homologous Mouse ModelsTransgenic Mouse ModelsTransplanted Tumor Mouse ModelsNon-Tumor-Bearing Immunodeficiency Mouse ModelsHIS Mouse ModelVarious methods of administration such as intravenous injection, intratumoral injection, and joint cavity injection are available.
  Content of drug safety evaluation：
  Single Dose Toxicity TestingRepeated Dose Toxicity TestImmunogenicity / ImmunotoxicityIn vitro Soft Agar Clone Growth TestIn vivo Tumorigenicity / TumorigenicityFormulation SafetyOther: Express Product Safety
  Reference：

  [1] Jing-E Zhou, et al. ShRNA-mediated silencing of PD-1 augments the efficacy of chimeric antigen receptor T cells on subcutaneous prostate and leukemia xenograft. Biomed Pharmacother. 2021 May;137:111339. doi: 10.1016/j.biopha.2021.111339.

Service Cases

• 

  Medicilon Helps iMBioRay's CAR-raNK Cell Therapy Approved Clinical Trial

Inquire

FAQs

• What is Car-T Cell Therapy?

  CAR-T immunotherapy (Chimeric Antigen Receptor T-cell Therapy) refers to the transfer of genetic material encoding specific antigen recognition domains and T cell activation signals into T cells through gene modification technology. This enables T cells to recognize and bind to specific antigens present on the surface of tumor cells, activating them to directly kill tumor cells by releasing perforins, granzyme B, etc. Additionally, CAR-T cells recruit endogenous immune cells by releasing cytokines, enhancing the immune system's ability to target and kill tumor cells. This approach aims to treat tumors effectively and can also establish memory T cells for sustained, specific anti-tumor effects.

• Preclinical Research Animal Models of Commonly Used CAR-T Cell Products

  a) Syngeneic Mouse model with a complete immune system
      Tumor bearing mouse
      Mouse-derived CAR-T cells used for on-target and off-target toxicity assessment

  b) Transgenic Mouse with a normal immune system
      Expresses human TAA
      Mouse-derived cells
      Proof-of-concept studies

  c) Human Xenograft Mouse Model
      Immuno-deficient mice
      Human-derived tumors
      Direct proof-of-concept studies

  d)  Humanized Immune System (HIS) Mouse Model
       Immune system-reconstituted humanized mice

• 所有研究均在同一园区内实验室有序完成，切实保证实验进度和项目沟通的高效性，占据数据获取和评估的行业优越性。